Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 16, 2017

Primary Completion Date

October 1, 2019

Study Completion Date

August 24, 2021

Conditions
Lymphoma, Non-HodgkinLymphoma, B-CellChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
BIOLOGICAL

CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)

"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 0: 2.5 x10\^5 CAR-20/19-T cells/kg (starting dose level)"

BIOLOGICAL

CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)

"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 1: 7.5 x10\^5 CAR-20/19-T cells/kg"

BIOLOGICAL

CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)

"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 2: 2.5 x10\^6 CAR-20/19-T cells/kg (goal cell dose)~Phase 1b Expansion Dose Level: 2.5 x 10\^6 cells/kg (single infusion)"

BIOLOGICAL

CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)

CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.

Trial Locations (1)

53226

Froedtert Hospital & Medical College of Wisconsin, Milwaukee

All Listed Sponsors
collaborator

Children's Hospital and Health System Foundation, Wisconsin

OTHER

lead

Medical College of Wisconsin

OTHER

NCT03019055 - Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell | Biotech Hunter | Biotech Hunter